Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010

详细信息    查看全文

• 作者：Orjana Velikonja MD (1)
  Milica Stefanovi? MD (1)
  Asst. Lidija Kitanovski MSc ; MD (1)
  Assist. prof. Helena Podgornik PhD (2)
  Assist. prof. Janez Jazbec PhD ; MD (1)
  
• 关键词：Acute myeloid leukemia ; Children ; Outcome ; Cancer treatment protocols ; Hematopoietic stem cell transplantation
• 刊名：memo - Magazine of European Medical Oncology
• 出版年：2014
• 出版时间：February 2014
• 年：2014
• 卷：7
• 期：1
• 页码：56-62
• 全文大小：456 KB
• 参考文献：1. Ching-Hong P. Childhood leukemias. Cambridge University Press; 2006.
  2. World health organization—Europe. Incidence of childhood leukemia. Fact sheet 4.1, December 2009, Code: RPG4_Rad_E1.
  3. Avcin S, Prelog T, Kavcic M, Kitanovski L, Anzic J, Benedik Dolnicar M, Rajic V, Zadravec Zaletel L, Debeljak M, Jazbec J. History of treatment and long-term outcome of childhood acute lymphoblastic leukemia in Slovenia. MEMO. 2011;4:178-3. CrossRef
  4. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 Trial From the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007-3. CrossRef
  5. Reinhardt D. Kooperative AML-BFM Therapiestudien [Internet]. Hannover: Medizinische Hochschule Hannover, Klinik und Poliklinik für Kinderheilkunde, P?diatrische H?matologie/ Onkologie; c 2005-013 [cited 2013 May 7]. Available at: http://aml.mh-hannover.de/
  6. Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer. 46:565-.
  7. Rubnitz J, Gibson B, Smith F. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010;24:35-3. CrossRef
  8. Smith M, Gloeckler Ries L, Gurney J, Ross J. Leukemia. SEER Pediatric Monograph, National Cancer Institute: 17-4.
  9. Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106(11):2495-02 CrossRef
  10. Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101(7):1677-4. CrossRef
  11. Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, D?hner H, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008;112:562-1. CrossRef
  12. Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Torsten H. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004;89:1082-0.
  13. Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001;15:1256-1. CrossRef
  14. Barnard DR, Lange B, Alonzo TA, Buckley J, Kobrinsky JN, Gold S, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 2002;100:427-4. CrossRef
  15. Ravindranath Y. Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer. 2005;44:1- (Commentary). CrossRef
  16. Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154:185-5. CrossRef
  17. Tilak V, Sookmane DD, Gupta V, Shukla J. Myelodysplastic syndrome. Indian J Pediatr. 2008;75(7):729-2. CrossRef
  18. Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29:310-5. CrossRef
  19. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030-2. CrossRef
  20. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499-06. CrossRef
  21. Kern W, Haferlach T, Schoch C, L?ffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
  22. Niewerth D, Creutzig C, Bierings MB, Kaspers GJL. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205-4. CrossRef
  23. Mlakar U. Treatment of acute myeloid leukemia in adults in the period 2008-011 at the university medical centre Ljubljana. Zdr.Vest. 2012;Supp. II:21-.
  24. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674-1. CrossRef
  25. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumors of hematopoietic and lymphoid tissues, 4th Edn. Geneva: WHO Press; 2008.
  
• 作者单位：Orjana Velikonja MD (1)
  Milica Stefanovi? MD (1)
  Asst. Lidija Kitanovski MSc, MD (1)
  Assist. prof. Helena Podgornik PhD (2)
  Assist. prof. Janez Jazbec PhD, MD (1)
  
  1. Department of Paediatric Oncology and Haematology, University Medical Center, Bohoriceva 20, 1000, Ljubljana, Slovenia
  2. Specialized Haematology Laboratory, Haematology Department, University Medical Centre, Zaloska 7, 1000, Ljubljanja, Slovenia
  
• ISSN：1865-5076

文摘

Background A review of treatment and survival of children with acute myeloid leukemia (AML) in Slovenia from 1991 to 2010. Methods We collected demographic data, information on the time, and course of treatment of patients with AML, which were classified in three risk groups and treated according to standard arm of BFM AML protocols 83, 93, 98, and 04. We assessed the rate of remission, event-free survival and overall survival, the incidence of relapse, the secondary neoplasms, secondary AML, the proportion of patients treated with hematopoietic stem cell transplantation (HSCT) and causes of death. The 2- and 5-year overall survival (5yOS) was estimated according to age group, risk group, the presence of remission, and the time of the treatment. Results There were 50 patients, 18 males (36-) and 32 females (64-) included in this study. Secondary AML was presented in four patients. Patients treated with HSCT were 18 (36-), 9 of them in first remission. The 2-year overall survival (2yOS) was 63.7?±-.8- and 5-year survival was 55.0?±-.2-. Differences in survival between age groups (0- years, 6-0 years and more than 10 years) was not significant. All patients in standard risk group lived for more than 2 years, in high-risk group 2yOS was 56.7?±-.7- (p--.05). Patients who were in remission before second treatment block had 2yOS 77.8?±-.4- and 5yOS 63.8?±-.8-, compared to the patients who were not in remission (2yOSand 5yOS 37.5?±-2.1-, p--.001). The 2yOS in patients treated with HSCT in first remission was 62-. There were 17 patients (34-) who had relapse of the disease, 23 (64-) patients died, 14 (61-) due to progression of the disease. Conclusions The results of treatment of AML in our center are comparable with other European centers. Survival was better in the standard risk group and in patients who were in remission before second treatment block. We observed a trend of improvement in survival in the time observed.